From fragile skin to living medicine: Lessons from RDEB
From BioSpace · · 21 min
This plays from the publisher's own server. We do not host a copy.
Description
In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We examine how recessive dystrophic epidermolysis bullosa serves as a model for cell and gene therapy, and what this ultra-rare disease teaches us about scaling advanced treatments for the future.
Host
Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace
Guests
Mark Lowdell (https://www.linkedin.com/in/mark-lowdell-3b98a129/), CSO & Co-Founder, INmuneBio Inc
Vishwas Seshadri (https://www.linkedin.com/in/vishwas-seshadri-6a27017/), CEO & Director, Abeona Therapeutics
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.